key: cord-0825382-lkeg2g24
authors: Daëron, Marc
title: Fc Receptors as Adaptive Immunoreceptors
date: 2014-05-13
journal: Fc Receptors
DOI: 10.1007/978-3-319-07911-0_7
sha: 3da462455f5bc2edd234206ccd5bdc9d16c50842
doc_id: 825382
cord_uid: lkeg2g24

Most biological activities of antibodies depend on their ability to engage Receptors for the Fc portion of immunoglobulins (FcRs) on a variety of cell types. As FcRs can trigger positive and negative signals, as these signals control several biological activities in individual cells, as FcRs are expressed by many cells of hematopoietic origin, mostly of the myeloid lineage, as these cells express various combinations of FcRs, and as FcR-expressing cells have different functional repertoires, antibodies can exert a wide spectrum of biological activities. Like B and T Cell Receptors (BCRs and TCRs), FcRs are bona fide immunoreceptors. Unlike BCRs and TCRs, however, FcRs are immunoreceptors with an adaptive specificity for antigen, with an adaptive affinity for antibodies, with an adaptive structure and with an adaptive signaling. They induce adaptive biological responses that depend on their tissue distribution and on FcR-expressing cells that are selected locally by antibodies. They critically determine health and disease. They are thus exquisitely adaptive therapeutic tools.

protect or kill recipients, when challenged with deadly pathogens or harmless doses of toxins, respectively.

One century later, we know that antibodies are responsible for these effects of immune serum, and that antibodies are immunoglobulins present in milligrams per milliliter in serum. Antibodies are the most abundant effector molecules of adaptive immune responses for the best and for the worst. Antibodies, indeed, protect from infectious diseases, they account for the long-term protection conferred by vaccines and they are increasingly used for passive immunotherapy. Antibodies are also responsible for diseases including allergies, hemolytic anemia of the newborn and several autoimmune diseases. How can antibodies exert both protective and pathogenic effects? One reason is that, by themselves, antibodies exert no biological effects.

Antibodies specifically bind to antigens and thereby generate immune complexes, but binding itself does nothing or very little to antigen. It was indeed found recently that both the neutralization of viruses and the neutralization of bacterial toxins, which have long been paradigmatic examples of biological properties of antibodies due to the masking of specific sites on antigens, require more than binding. They require the Fc portion of antibodies and depend on receptors for antibodies (Joller et al. 2010; Mallery et al. 2010) . For antibodies to affect antigens, they indeed need not only to bind to antigen epitopes through their Fab portions, but also to interact through their Fc portion with effector systems. These include soluble molecules such as components of the enzymatic cascade of Complement, and cells that express receptors for the Fc portion of antibodies (FcRs).

As FcRs can trigger positive and negative signals, as these signals control a variety of biological activities in a given cell, as FcRs are expressed by cells of many types, as these cells express various combinations of FcRs, and as FcRexpressing cells have different functional repertoires, antibodies can exert a wide spectrum of biological activities. Understanding how antibodies work is not only an exciting endeavor to comprehend the complexity of immune responses, it is also a requirement for whom aims at developing new vaccines or therapeutic antibodies.

I will argue that FcRs are unique immunoreceptors with no predetermined specificity, structure, signaling or biological properties. Actually, FcRs are not functional until they are engaged by immune complexes on cell membranes. Then and there, they can build up a multiplicity of superstructures capable of triggering a wide functional repertoire of adaptive responses to the multitude of antigenic stimuli.

The term ''immunoreceptor'' was coined following impassioned discussions at a meeting held in Kecskemét, Hungary, in September 1994 , to designate receptors involved in antigen recognition and possessing intracellular tyrosine-based activation motifs. The term ''Immunoreceptor'' was rapidly adopted and used to designate not only receptors containing such Immunoreceptor Tyrosine-based Activation Motifs (ITAMs) (Reth 1989; Cambier 1995) , but also receptors containing Immunoreceptor Tyrosine-based Inhibition Motifs (ITIMs) that were soon described (Daëron et al. 1995a) . ''Immunoreceptor'' is a loose term. Its use became even looser when ITIMs were found in innumerable molecules with no evident link with immunity .

Several ITAMs and one ITIM having been identified in their intracytoplasmic domains, FcRs were promoted immunoreceptors, just like antigen receptors expressed by B cells (BCRs) and antigen receptors expressed by T cells (TCRs). The word forged the concept. FcRs ''recognize'' neither native antigens as BCRs do, nor the association of antigen-derived peptides and Major Histocompatibility Complex molecules expressed by antigen-presenting cells as TCRs do. FcRs, however, ''recognize'' antigen-antibody complexes. Immune complexes are the third form under which any given antigen can interact with and deliver signals to cells of the immune system. FcRs are immunoreceptors of the third type.

Unlike BCRs and TCRs, whose expression is restricted to B and T lymphocytes, respectively, FcRs are widely expressed, including by most cells of the myeloid lineage. Unlike lymphocytes, myeloid cells need neither to proliferate nor to differentiate in order to be functional; they can perform a variety of biological processes; they are abundant in the blood stream and ubiquitous. Myeloid cells are the effectors of innate immunity. They are equipped with a variety of patternrecognition receptors for molecules that are widely shared by micro-organisms, but they have no antigen receptors. Their FcRs, however, enable them to interact specifically with antigens. When binding to FcRs, antibodies indeed endow these cells with bona fide antigen receptors. Through FcRs, antibodies enroll myeloid cells in adaptive immune responses. As a consequence, adaptive immunity uses the same effector cells as innate immunity.

Unlike BCRs and TCRs, which contain built-in antigen-specific subunits, FcRs have no antigen-recognition structures. They have therefore no predetermined antigen specificity. They can, however, adopt any antigen specificity. Specificity is provided by antibodies that bind to FcRs (Fig. 1) . The fact that antigen specificity is dissociated from receptors enables FcR-expressing cells to act on any antigen the adaptive immune system is confronted to and responds to by the production of antibodies. Although devoid of antigen-recognition capability, FcRs can therefore provide myeloid cells with the whole cognitive repertoire of B cells.

The specificity of individual BCRs and TCRs results from one combination of variable gene segments among the many possible combinations that form the B and T cell potential repertoires. The specificity of individual FcRs is that of the subset of antibodies of the B cell actual repertoire, which were synthesized by B cell-derived plasma cells and which happened to bind to FcRs. The specificity of BCRs and TCRs is selected a priori from a potential combinatorial diversity of gene segments, whereas that of FcRs is selected a posteriori from an actual diversity of proteins.

Unlike B and T cells which express BCRs or TCRs of one specificity only, FcRexpressing cells can carry a multiplicity of antibodies of different specificities. Antibody responses are indeed polyclonal. They generate antibodies against several antigens, and antibodies against one antigen can be directed to several epitopes. As antibodies bind to FcRs irrespectively of the specificity of their Fab portions, and as cells express large numbers of FcRs-from a few thousands to one million per cell-every FcR-expressing cell can respond simultaneously to a multitude of antigens.

Antibodies bind to FcRs with a variable affinity. The binding of antibodies to FcRs is reversible and it obeys the mass action law (Kulczycki and Metzger 1974) :

The affinity of FcRs is characterized by an affinity constant (K a ) which is the quotient of an association constant (k a ) divided by a dissociation constant (k d ). The affinity constant is a characteristic of the FcR.

ITAMs ITIM Ag Ag Fig. 1 Differential binding of antibodies and antigen to high-affinity and to low-affinity FcRs. Antibodies bind first to high-affinity FcRs, then antigen binds to receptor-bound antibodies (left). Antigen binds first to antibodies and form immune complexes that can then bind to low-affinity FcRs (right). The order of events is different but the result is the same: FcRs are aggregated The binding of antibodies to FcRs depends on the K a of receptors, but also on the relative concentrations of ligands, i.e, the concentration of antibodies in the environment and the density of receptors on the cell surface. It also depends on the glycosylation of antibodies. Finally, the affinity of FcRs determines their specificity for immunoglobulin classes and subclasses.

High-affinity FcRs can bind monomeric immunoglobulins in the absence of antigen, i.e., not as immune complexes (Fig. 1) . A proportion of high-affinity FcRs may therefore be occupied in vivo. Antibodies however may dissociate from highaffinity FcRs, which makes receptors available for binding other antibodies. The dissociation constant of high-affinity FcRs therefore critically determines their availability for other antibodies present in the environment. This can be exemplified by the murine high-affinity receptor for IgG2 FccRIV (K a for IgG2a ± 3 9 10 7 M -1 ). We found that this receptor is also a low-affinity receptor for IgE (Ka ± 5 9 10 5 M -1 ), and we wondered whether this property is biologically meaningful. One indeed expects FccRIV to be saturated by IgG2 in vivo, and thus unavailable for IgE. We found that the half life of IgG2 on FccRIV is of a few minutes only at 37°C, and that IgE immune complexes can perfectly replace IgG2 on FccRIV in the presence of normal serum (Mancardi et al. 2008 ). On the contrary, the extremely high affinity constant (Ka ± 10 9 -10 10 M -1 ) of FceRI, the high-affinity receptors for IgE expressed by mast cells and basophils in mice and humans, is due to an extremely low dissociation constant (Kulczycki and Metzger 1974) . As a consequence, IgE antibodies remain bound to FceRI for extended periods of time, in spite of their extremely low plasma concentration.

The affinity of low-affinity FcRs (Bruhns et al. 2009 ) is too low for enabling them to bind monomeric antibodies. They can however bind antibodies as multivalent immune complexes with a high avidity (Fig. 1) . As a consequence, in the absence of antigen, low-affinity FcRs (e.g., FccRs) remain free in spite of the high concentration of circulating immunoglobulins, (e.g., IgG). They are therefore available for immune complexes whenever these come close enough. Immune complexes bind to low-affinity FcR-expressing cells because antibodies are concentrated on multivalent antigens in immune complexes and because many antibodies can bind at the same time to many FcRs on the same cell membrane. Once bound to FcRs, immune complexes remain on low-affinity FcR-expressing cells because antibodies that dissociate from individual FcRs are rapidly replaced by other antibodies present in the complex. Antibodies that dissociate from FcRs and remain bound to antigen can also engage FcRs that were not previously engaged. The interactions of immune complexes with low-affinity FcRs are therefore at the same time labile and stable; they are highly dynamic.

When low-affinity FcRs interact with immune complexes, the concentration and the composition of immune complexes therefore determine the avidity with which these bind to receptors. Indeed, what matters for binding is the local concentration of Fc portions. This concentration depends on the density of epitopes that are present on the antigen molecule and that are recognized by antibodies involved in the immune complex. Antibodies of the same specificity can therefore bind with different avidities to the same FcRs when in complex with antigens that have a high density of specific epitopes and when in complex with antigens that have a low density of the same epitopes (Fig. 2 ). An interesting situation is the interaction with FcRs of antibodies against cell surface antigens. The possibility that target cells may express FcRs is rarely considered. Antibodies are therefore viewed as binding in trans, to target cell antigens via their Fab portions and to effector cell FcRs via their Fc portion. If target cells express FcRs, antibodies can bind in cis, i.e., to target antigens via their Fab portions and to FcRs via their Fc portion on the same cell (Fig. 3 ). Binding to antigens located on the same membrane as FcRs markedly enhances the local concentration of antibodies as they are concentrated in a plane rather than dispersed in a volume. Binding to FcRs is also enhanced by the local concentration, i.e., the density, of specific epitopes on the cell membrane. Such an Fc-FcR cis binding was demonstrated to trigger mast cell activation using alloantibodies against MHC class I antigens expressed by the same cells (Daëron et al. 1975; Daëron and Voisin 1978) . It was extensively used to inhibit B cell activation using anti-immunoglobulin IgG antibodies (Phillips and Parker 1983) . One can expect cis binding to apply for many monoclonal antibodies used for passive immunotherapy.

The affinity with which immunoglobulins bind to FcRs further depends on the glycosylation of their Fc portion (Arnold et al. 2007 ). Thus, each heavy chain of IgG1 contains a single covalently attached biantennary N-glycan at the highly

The avidity with which immune complexes bind to FcRs is determined by:

The adensity of FcRs on cell membranes Y Y Y Y Y Fig. 2 Modulation of the binding avidity with which immune complexes bind to FcRs. The binding avidity varies with the density of epitopes on antigen and with the density of FcRs on cell membranes conserved N 297 residue in its CH 2 domain. Point mutations of this glycosylation site abrogate the ability of IgG antibodies to bind to FccRs. If engineered with such a mutation (e.g., N 297 Q), aglycosylated antibodies therefore no longer engage FccRs and they can be used as blocking-only molecules (Veri et al. 2007) . Noticeably, N 297 mutations do not affect the binding of IgG to neonatal FcRs (FcRn), which protect IgG from degradation.

The Ka of the various mouse and human FcRs spans over at least five Logs. Highaffinity FcRs, defined operationally by their ability to bind monomeric immunoglobulins, have a Ka ranging from 10 7 to 10 10 M -1 . Low-affinity FcRs, defined as being unable to bind monomeric immunoglobulins but as being able to bind immune complexes, have a Ka ranging from 10 5 to 10 7 M -1 (Bruhns et al. 2009 ). Most FcRs do not appear to be specific for one class or subclass of immunoglobulins. Mouse FccRIIB and FccRIIIA bind mouse IgG1, IgG2a and IgG2b. Likewise, human FccRIIA, FccRIIB, and FccRIIIA bind all four subclasses of human IgG. However, the affinity of these three receptors is much lower for IgG2 and, to a lower extent, for IgG4 than for IgG1 and IgG3. Noticeably, human FccRIIB has a lower affinity than any other FccR for all four subclasses of human IgG (Bruhns et al. 2009 ). pIgR can bind both dimeric IgA and pentameric IgM

Cis-binding (Bakos et al. 1991) . FccRIV are both high-affinity receptors for mouse IgG2a and IgG2b and low-affinity receptors for mouse IgE (Mancardi et al. 2008) . Likewise, the murine low-affinity receptors for mouse IgG FccRIIB and FccRIIIA were found to bind also mouse IgE (Takizawa et al. 1992) . Whereas the affinity of these receptors for mouse IgG1, IgG2a and IgG2b is between 3 9 10 5 and 3 9 10 6 M -1 , their affinity for mouse IgE is in the order of 2 9 10 4 M -1 only (Mancardi et al. 2008) . This is an extremely low affinity, at the limit of nonspecificity.

This poses the question of the specificity of FcRs. As discussed above, FcRs display a gradient of affinities for the various isotypes of immunoglobulins. This gradient is extremely wide, and it seems continuous. The specificity of FcRs for immunoglobulin classes and subclasses therefore appears more quantitative than qualitative, and what determines the specificity of FcRs is a large enough difference of affinities for different immunoglobulins.

The structure of FcRs was determined and refined by biochemical, genetic and proteomic approaches, as they became available. Altogether, these studies provided solid grounds for elaborating widely used 2D-and 3D-models of FcRs (Garman et al. 1998; Maxwell et al. 1999; Sondermann et al. 1999; Ding et al. 2003) . As such, however, these models represent FcRs as they are when they are not functional. They show building blocks. Except FcRn, which bind IgG intracellularly in acidified vacuoles (Rodewald and Kraehenbuhl 1984) , functional FcRs are receptors engaged on cell membranes by immune complexes. They are superstructures made with these building blocks. FcR engagement indeed associates various numbers of FcRs in various combinations to generate superstructures of various compositions.

Classically, FcRs have a structure similar to that of BCRs and TCRs. The vast majority of them are made of 2-3 noncovalently associated subunits: a ligandbinding subunit (FcRa) that has an affinity for various classes and subclasses of immunoglobulins, and one or two ITAM-containing signaling subunits (FcRc and FcRb) shared by multi-subunit FcRs (Fig. 1) .

FcRa altogether form a family of polypeptides with 2-5 extracellular immunoglobulin-binding domains that have a secondary structure typical of Immunoglobulin Superfamily (IgSF) molecules, a hydrophobic transmembrane domain and a nonstructured intracytoplasmic domain of variable length. FcRa with different extracellular domains are the core structure of receptors for IgA (FcaR), IgG (FccR and FcRn) and IgE (FceR) (Hulett and Hogarth 1994) . Binding involves the hinge between the two juxta-membrane extracellular domains of FcRs and the penultimate constant domain of immunoglobulin heavy chains. FcRn are unique MHC class I-like molecules that bind the Fc portion of IgG with a high affinity (Burmeister et al. 1994) .

FcRc is a widely expressed homodimer made of two disulfide bond-linked polypeptides highly conserved in mice and humans (Orloff et al. 1990 ). It is shared by all activating multi-chain FcRs. FcRb is a 4-transmembrane domain polypeptide that associates with multi-chain FcRs expressed in mast cells and basophils (Kinet et al. 1988 ). Multi-chain FcRs must associate with at least one specific subunit in order to be expressed. Most need FcRc (Lobell et al. 1993; Takai et al. 1994; Letourneur et al. 1995) . The expression of these receptors therefore depends on the tissue distribution of FcRc, and FcRc-deficient mice have no activating FcR (Takai et al. 1994) . Mouse FceRI, but not human FceRI, also need to associate with FcRb (Kinet 1999) . As FcRb is expressed by mast cells and basophils only in both species, the expression of FceRI is restricted to these cells in mice (Kinet et al. 1988 ), but not in humans (Gounni et al. 1994 (Gounni et al. , 2001 Joseph et al. 1997 ). FcRn do not associate with FcRc or with another ITAM-containing subunit, but with b2 microblobulin and this association is mandatory for FcRn to be expressed (Israel et al. 1995) .

Few FcRs are single-chain receptors. FccRIIA and FccRIIC (in humans) and FccRIIB (in mice and humans) have two extracellular domains that bind IgG with a low affinity. Human FccRIIB and FccRIIC have the same extracellular domains. FccRIIA and FccRIIC have the same intracytoplasmic domain (Ravetch and Kinet 1991) . FccRIIA and FccRIIC contain one ITAM whereas FccRIIB contain one ITIM. FccRIIA and FccRIIC are the only ITAM-containing single-chain FcRs. FccRIIA were however reported to form homodimers constitutively on cell membranes without delivering activation signals in the absence of ligand (Powell et al. 2006) . FccRIIIB are glycosyl-phosphatidylinositol-anchored single-chain FcRs unique to humans. They bind human IgG with a low affinity. FcRs for polymeric immunoglobulins (pIgR) have 5 extracellular domains that bind dimeric IgA and pentameric IgM. They are not known to associate with ITAM-containing subunits.

Other FcRs that do not associate with FcRc or FcRb, do not belong to the IgSF but to the C-type lectin superfamily. These FcRs bind IgE (FceRII) (Conrad 1990 ). Binding, however, does not involve the interaction of sugar residues, which are abundant in the Fc portion of IgE, with the extracellular lectin domain of FceRII. The affinity of FceRII for IgE is relatively low. However, FceRII are expressed as homotrimers which can bind IgE immune complexes with a high avidity (Kilmon et al. 2004 ). They are not known to associate with signaling subunits.

Like BCRs and TCRs, FcRs are aggregated by plurivalent ligands. Unlike BCRs and TCRs, however, FcRs form hetero-aggregates. Because BCRs and TCRs with a single specificity are expressed on B and T cells, they can form homo-aggregates only, when engaged by naked antigen or peptide-MCH complexes, respectively. FcRs can also form homo-aggregates when engaged by immune complexes made with monoclonal antibodies of a single specificity as they are commonly used in the laboratory. Engaging FcRs under these conditions has been instrumental for establishing the binding parameters of FcRs and for elucidating the mechanisms of signal transduction used by FcRs. This experimental situation, however, is an artifact.

Immune responses are indeed not only polyclonal, but also pluri-isotypic. No immunization procedure induces a single class of antibodies. Depending on the concentration of antigen, depending on the adjuvant, depending on the route of immunization, some isotypes of antibodies can be favored, but in all cases, the overall isotypic pattern of the response is not markedly altered. Even when immunizing mice with protocols that promote strong Th1 responses, such as one injection of a high concentration of proteins in Freund's complete adjuvant followed by repeated injections of the same high dose of antigen in incomplete Freund's adjuvant, IgG1 antibodies remain, by far, the dominant isotype of antibodies, and detectable levels of IgE antibodies can even be observed in serum . As a consequence, immune complexes that form in vivo contain antibodies of several classes and subclasses. As FcRs with different specificities are co-expressed by most FcR-expessing cells, pluri-isotypic immune complexes engage several types of FcRs on cell membranes. When aggregated under physiological conditions, FcRs form hetero-aggregates.

The composition of FcR hetero-aggregates depends on multiple parameters. It depends on the FcRs that are expressed by a given cell at a given time and in a given place. it depends on the respective local concentration of antibodies of the different isotypes. It depends on the nature and on the concentration of antigen present in the environment (Fig. 4) . FcR hetero-aggregates of different compositions may have markedly different signaling properties.

FcRs trigger no signal when binding immunoglobulins. They signal when aggregated (Metzger 1992) . The sequence of events that lead to receptor aggregation is different for high-affinity and low-affinity FcRs (Fig. 1) . Monomeric antibodies bind first to high-affinity FcRs that are aggregated afterwards, when a plurivalent antigen binds to receptor-bound antibodies. Antibodies bind first to antigen, generating immune complexes that can bind to and, therefore, simultaneously aggregate low-affinity FcRs. The result, however, is the same: receptor aggregation. The nature of signals depends primarily, but not exclusively, on molecular motifs contained in the intracytoplasmic domains of FcRs or of their subunits. FcRs can generate activation signals and/or inhibition signals. (Powell et al. 2006) . The significance of the presence of several ITAMs in immunoreceptors is unknown. One ITAM is enough as the aggregation of singlechain chimeric molecules with the intracytoplasmic domain of FcRc, FcRb, TCRf activated the transfected cells in which they were expressed (Daëron et al. 1995a) , although Iga and Igb triggered different Ca 2+ signals in B cells (Choquet et al. 1994 ) Upon receptor aggregation, ITAMs are phosphorylated by src family tyrosine kinases. This intracellular chemical perturbation initiates the constitution of dynamic intracellular signalosomes, in which activation signals are generated. Signalosomes build up on tyrosine-rich transmembrane adapter proteins that reside constitutively in lipid-rich membrane microdomains (Bezman and Koretzky 2007) . Signals propagate intracellularly via various metabolic pathways that altogether lead to gene transcription, activation of the lipid metabolism and membrane alterations associated with exocytosis.

The isotypic composition of the Ab response

The FcRs that are expressed on a given cellat a given time at a given place

The relative concentration of antibody classes in tissues and their for these FcRs

Adaptive FcR complexes formed on cell surfaces upon receptor engagement. FcR complexes with variable compositions and sizes build up on cell membranes, depending on the FcRs expressed on cells, the isotypic composition of the antibody response, the local concentration of antibodies of the various classes and subclasses, the antigen specificity of these antibodies and the local concentration of antigen ITAM-containing FcRs also generate inhibition signals. Inhibition signals generated by activating FcRs such as FceRI can be readily observed when challenging mast cells sensitized with IgE antibodies by increasing concentrations of specific antigen. Mast cell degranulation dose-dependently increases up to a maximum. Degranulation thereafter decreases rapidly down to background levels. This inhibition in excess of antigen has long been interpreted as resulting from a reduced ability of antigen to aggregate efficiently FceRI (Wofsy et al. 1978) . Inducible phosphorylation of intracellular proteins, however, keeps increasing beyond the optimal concentration of antigen. Moreover, inhibition in excess of antigen is abrogated in mast cells from mice deficient for the SH2 domain-containing inositol phosphatase SHIP1 (Gimborn et al. 2005) . Finally, mast cells from SHIP1-deficient mice display enhanced degranulation responses to optimal and suboptimal antigen concentrations (Huber et al. 1998) . FceRI therefore generate SHIP1-dependent inhibition signals both when suboptimally or optimally aggregated and when supra-optimally aggregated by antigen. Similar effects of SHIP1 deficiency were observed with other activating FcRs (Nakamura et al. 2002) . ITAM-containing FcRs therefore generate a mixture of activation and inhibition signals (Malbec et al. 2004) . Activation signals are dominant over inhibition signals under physiological conditions.

FccRIIB are the only ITIM-containing FcRs. The same ITIM is present in the intracytoplasmic domain of all murine and human FccRIIB isoforms (Daëron et al. 1995a ). FccRIIB are not tyrosyl-phosphorylated and they trigger no intracellular signal when aggregated. They trigger negative signals when they are co-aggregated with activating receptors by immune complexes (Daëron et al. 1995b) . Under these conditions, the ITIM of FccRIIB is phosphorylated by the same src-family tyrosine kinase that phosphorylates ITAMs in activating receptors (Malbec et al. 1998) . The SH2 domain of SHIP1 having a high affinity for the phosphorylated FccRIIB ITIM (Bruhns et al. 2000) , large amounts of SHIP1 are recruited and brought into signalosomes generated by activating FcRs (Lesourne et al. 2001) . FccRIIB therefore potentiate SHIP1dependent negative signals generated by ITAM-containing FcRs (Lesourne et al. 2005) , and inhibition signals become dominant over activation signals.

Negative regulation of ITAM-containing FcRs by FccRIIB is one example of hetero-aggregation that critically affects FcR signaling. It is a widely occurring situation. Hetero-aggregation, whether the co-aggregation of different types of FcRs or the co-aggregation of FcRs with other immunoreceptors, is actually a rule, rather than an exception, under physiological conditions. Hetero-aggregation can involve activating FcRs only. This happens when pluriisotypic immune complexes engage FcRs for different immunoglobulin classes on cells that express the corresponding ITAM-containing FcRs. One exemple can be human skin mast cells sensitized with IgE antibodies and exposed to immune complexes containing IgG antibodies against the same antigen. Due to the high concentration of IgG antibodies, allergens are likely to be in complex with IgG when they reach FceRI-bound IgE on tissue mast cells. Human skin mast cells express FceRI and FccRIIA, but no FccRIIB (Zhao et al. 2006) . As a result, FceRI and FccRIIA are co-engaged on human mast cells. Activation signals by FceRI are not identical as signals generated by FccRIIA because these receptors contain different ITAMs. Both types of signals are expected to be integrated and to lead to cell responses that may differ from signals generated by FceRI or by FccRIIA alone.

Hetero-aggregation can involve inhibitory FcRs and activating FcRs of identical or different specificities for immunoglobulins. One example of heteroaggregation of FcRs of identical specificity is when human or mouse basophils are challenged with IgG immune complexes. Basophils from both species co-express ITAM-containing and ITIM-containing receptors for IgG: human basophils express FccRIIA and FccRIIB, whereas mouse basophils express FccRIIIA and FccRIIB. Basophils from both species, however, fail to be activated by IgG immune complexes. The reason is that FccRIIB-dependent inhibition is dominant over FccRIIA-or FccRIIIA-dependent activation in these cells (Cassard et al. 2012 ). An example of hetero-aggregation of FcRs of different specificities is when the same cells are sensitized with IgE and challenged with IgG immune complexes. Under these conditions, IgG immune complexes co-aggregate not only the ITAM-and ITIM-containing FccRs, but also the ITAM-containing FceRI. In both cells, FceRI-dependent responses are negatively regulated by FccRIIB (Cassard et al. 2012) . IgG antibodies therefore control IgE-mediated human and mouse basophil activation.

Hetero-aggregation can involve FcRs and non-FcR immunoreceptors, for instance when cells express one type of FcR only. Immune complexes can coengage these FcRs, whether inhibitory such as FccRIIB in B cells or activating such as FccRIIIA in NK cells, with other immunoreceptors, whether activating such as BCRs in B cells or inhibitory such as Killer cell Inhibitory Receptors with a long intracytoplamsic domain (KIRLs) in NK cells. As a consequence, BCR signaling is negatively regulated by FccRIIB in B cells (Phillips and Parker 1983; Amigorena et al. 1992 ) and FccRIIIA signaling is negatively regulated by KIRLs in NK cells (Moretta et al. 1997 ).

All the above considered, FcR signaling appears exquisitely susceptible to control and/or to be controlled by other FcRs and/or by other immunoreceptors that are co-engaged in FcR superstructures by immune complexes. Ensuing biological responses may therefore be tightly controlled as a function of antibodies and antigen present in the environment.

If biological responses triggered by FcRs depend quantitatively on the superstructures built-up on cell membranes by immune complexes, they depend qualitatively on the cell types on which these superstructures form. FcRs do not induce unique biological responses, but biological activities that can be induced by other receptors in the same cell. However, unlike BCRs and TCRs, which induce both cell activation and proliferation, ITAM-containing FcRs induce cell activation only.

Superstructures that build-up on cell membranes depend on which FcRs are available for immune complexes on the cell membrane, i.e., on the tissue distribution of FcRs. Cells of hematopoietic origin express a combination of FcRs that is typical of the cell type (Fig. 5) . (Cassard et al. 2002) , also express FcRs. FcRn are expressed by many cells including epithelial cells, monocytes, macrophages, dendritic cells, neutrophils, hepatocytes (Ghetie and Ward 2000) .

Activating FcRs are expressed by myeloid cells and by lymphoid cells with no classical antigen receptor, i.e., NK cells (Perussia et al. 1989 ) and intraepithelial c/ dT cells of the intestine (Deusch et al. 1991; Sandor et al. 1992; Woodward and Jenkinson 2001) . They are not expressed by mature T and B lymphocytes. Lymphocytes therefore do not express more than one type of antigen receptor, and activating FcRs do not interfere with lymphocyte activation triggered by clonally expressed antigen receptors. Low levels of FccRIIIA were however found on a subset of murine CD8 T cells and they efficiently triggered antibody-dependent cell-mediated cytotoxicity (Dhanji et al. 2005) .

FccRIIB are expressed by most myeloid cells and by B lymphocytes. NK cells and T cells, which do not express FccRIIB, express several other inhibitory receptors involved in cell-cell interactions (Long 1999) . FccRIIB have a more restricted tissue distribution in humans than in mice.

Few cells express one type of FcR only. These are B cells, which express FccRIIB only in both mice and humans, and NK cells, which typically express FccRIIIA only in both mice and humans. A SNP in the FCGR2C gene, however, determines the expression FccRIIC by NK cells in human donors (van der Heijden et al. 2012). Other cells express several FcRs. All express IgG receptors and, in humans, IgA receptors. Monocyte/macrophages express more types of FccRs than other hematopietic cells. FccRIIA are expressed by all these human cells. Monocytes express higher levels of FccRIIA than other blood leukocytes. Basophils express much higher levels of FccRIIB than other blood cells, including B cells (Cassard et al. 2012) .

Such a wide tissue distribution of FcRs endows antibodies with a wide spectrum of biological properties. These depend on the functional repertoire of FcR-expressing cells. All cell types can endocytose, some only can phagocytose, and even less can transcytose. The many cells that express FcRn can pinocytose and release IgG molecules that bound to FcRn intracellularly, thereby protecting them from lysosomal degradation. Some cells can expel granules that contain cytotoxic mediators, other cells granules that contain vasoactive or pro-inflammatory mediators and proteases. Many cells can synthesize cytokines, chemokines or growth factors of 

Due to the differential tissue distribution of FcRs, antibodies select FcR-expressing cells involved in biological responses. FcRs therefore determine which cells are engaged by specific classes and subclasses of antibodies. As discussed above, the outcome depends on the functional repertoire of these cells. This can be exemplified by the analysis of cell types involved in systemic anaphylaxis. Because IgE-induced passive systemic anaphylaxis (PSA) was abrogated in FceRI-deficient mice (Dombrowicz et al. 1993) , in mast cell-deficient mice (Kalesnikoff and Galli 2010; Feyerabend et al. 2011) , and in histidine decarboxylase-deficient mice (Makabe-Kobayashi et al. 2002) , histamine release by mast cells triggered by the aggregation of FceRI upon binding of antigen to receptorbound IgE became the paradigmatic model of anaphylaxis. This widely accepted interpretation forgot IgG-induced passive anaphylaxis described by Zoltan Ovary in the 1950s (Ovary 1952a, b) , before IgE antibodies were discovered (Ishizaka et al. 1966 ). IgG1-induced PSA was later shown to depend on FccRIIIA (Miyajima et al. 1997) . Responsible cells, however, still remain unidentified as this reaction was not abrogated in mast cell (Miyajima et al. 1997) or in basophil deficient mice (Ohnmacht et al. 2010) . More recently, we found that mice lacking FceRI and FceRII or FccRIIIA developed active systemic anaphylaxis (ASA) as severe as did wild-type mice, when immunized with antigen in complete Freund's adjuvant and challenged with antigen intravenously. Likewise, using quintuple FcR-deficient (5KO) mice that express one activating FcR only, the high-affinity receptor for IgG2 FccRIV expressed by monocyte/macrophages and by neutrophils, we unraveled the unexpected role of neutrophils in ASA .

The reason explaining these seemingly discrepant findings is that each class or subclass of antibodies does not select the same cell types (Fig. 5) . IgE can engage FceRI-expressing cells only, i.e., mast cells and basophils in mice, whereas IgG2 can engage FccRIV-and FccRI-expressing cells, i.e., monocyte/macrophages and/ or neutrophils, and IgG1 can engage the many cells that express FccRIIIA.

Because immune responses are pluri-isotypic and because cells of different types share receptors for the same isotypes, antibodies select heterogeneous cell populations, rather than homogeneous single-cell populations, when in complex with antigen. These populations consist of a mixture of various FcR-expressing cells that are either present or recruited by chemokines and/or proliferate in response to growth factors, at the site of the reaction. Biological processes in which FcRs are involved are therefore a resultant of the responses of the many cells that are engaged in the reaction at a given place and at a given time.

If one keeps considering ASA as an example, most cell types that were individually found to contribute to this reaction are present together in the blood stream where antibodies circulate and into which the challenging antigen is injected. The relative contribution of these cells therefore depends on the relative concentrations of the different classes and subclasses of antibodies, on FcRs expressed by these cells and on the interplay between FcRs.

IgG1 is the dominant isotype of antibodies following immunization by antigen in Freund's adjuvant, and FccRIIIA are the only activating FcRs with an affinity for IgG1. Mouse mast cells (Malbec et al. 2007 ) and basophils (Cassard et al. 2012 ) express FccRIIIA. Mast cells are not expected to be numerous in blood. Basophils are not expected to play a critical role either, as they express high levels of FccRIIB that prevent IgG1-induced basophil activation (Cassard et al. 2012) . Other cells that express FccRIIIA are neutrophils and monocyte/macrophages. IgG2 is much less abundant than IgG1. FccRI, FccRIIIA, and FccRIV are activating receptors that have an affinity for IgG2. IgG2-induced PSA was observed in 5KO mice that express FccRIV only and neutrophils was demonstrated to contribute to this shock . IgE are between five hundred thousandand one million-fold less abundant than IgG1 antibodies. They can bind primarily to FceRI, but also to FccRIV. As IgE-induced PSA was abrogated in 5KO mice, FccRIV are unlikely to contribute to the part of ASA that depends on IgE. Mast cells and basophils remain the likely candidates. These data altogether indicate that IgE, IgG1, and IgG2 can all induce anaphylaxis when engaging FceRI, FccRIIIA, and FccRIV on mast cells, basophils, and neutrophils, respectively.

Selective depletion experiments in wild-type mice could clarify the respective roles of these cells in ASA. Neutrophil depletion markedly reduced ASA in wildtype mice, basophil depletion resulted in a milder but significant reduction, and the depletion of both basophils and neutrophils virtually abrogated the reaction. Noticeably, ASA could be induced in mast cell-deficient mice, confirming the expected insignificant contribution of these cells to ASA. Neutrophils and to a lower extent basophils are therefore the main effectors of ASA, neutrophils being involved via FccRIIIA by IgG1 and to a lower extend via FccRIV by IgG2, and basophils being involved via FceRI by IgE.

As discussed above, antibodies can trigger the release of potentially harmful-in some cases, life-threatening-inflammatory mediators. They can also induce destructive cytotoxic mechanisms. Antibodies are therefore potentially pathogenic.

This may be the price to pay for having efficient antibodies in protective immunity. The activating properties of antibodies are however (or therefore?) tightly controlled by regulatory mechanisms. As a consequence, immune responses are normally nonpathogenic. Typically, the induction phase of adaptive immune responses is initiated in the periphery, while effectors are generated centrally and diffuse throughout the body. The antibody response is an example. Although they may be systemic as in anaphylaxis, many biological effects of the effector phase of immune responses take place locally. They therefore depend on local conditions. As a consequence, they are cell-or tissue-specific, pleiotropic and sometimes antagonistic. Below are examples of opposite or unexpected effects, i.e., of the complexity of the FcRdependent effects of antibodies.

Antibodies are potent adjuvants. In spite of their low plasma concentration, IgE antibodies enhance antigen presentation by B cells. IgE immune complexes indeed engage B cell FceRII, leading to an efficient antigen presentation to T cells (Getahun et al. 2005; Hjelm et al. 2006) . As a result, IgE antibodies enhance the production of all classes of antibodies. IgG antibodies also behave as adjuvants through the uptake of antigen-IgG antibody complexes by dendritic cells via activating FccR. As a consequence, both MHC class II presentation (Heyman 1990 ) and MHC Class I cross presentation (Machy et al. 2000) are enhanced. Expectedly, activating FccRdependent presentation of antigen-antibody complexes is counterbalanced by FccRIIB expressed by dendritic cells (Kalergis and Ravetch 2002) . FccRIIB, however, can promote ''antigen presentation'' to B cells by follicular dendritic cells (Mond et al. 1995) . FccRIIB expressed by these cells can indeed be engaged by the Fc portion of immune complexes and prevent them from coengaging FccRIIB with BCRs on B cells (El Shikh et al. 2006) . Antigen in immune complexes bound onto follicular dendritic cells are thus more potent inducers of antibody responses than free antigen, whether in vitro (Tew et al. 2001) or in vivo (Wu et al. 2008; El Shikh et al. 2009 ).

Unlike immune responses to soluble antigen that are markedly enhanced by IgG antibodies, immune responses to particulate antigens are well known to be suppressed by IgG antibodies. Minute amounts of specific IgG can indeed suppress an anti-heterologous erythrocyte immune response, whether primary or secondary. This observation, first made in the 1960s (Henry and Jerne 1968) , has been the rationale for injecting Rhmothers who have given birth to Rh + babies with anti-RhD antibodies, as a preventive treatment of hemolytic disease of the newborn. When FcR-deficient mice became available, it was unexpectedly found that FccRIIB-dependent negative regulation does not account for this feedback regulation by antibodies. This regulation was unaltered not only in FccRIIBdeficient mice (Heyman et al. 2001 ), but also in mice lacking all FccR (Karlsson et al. 1999) . The mechanism behind inhibition remains unclear.

Antiviral antibodies may profoundly affect viral infection by FcR-dependent mechanisms. It was recently reported that the neutralizing effect of antibodies depends on the interaction of their Fc portion with a unique intracellular FcR named TRIM21, and the subsequent degradation of virus-antibody complexes by the proteasome (Mallery et al. 2010) . Classical activating FcRs are also needed to clear influenza virus (Huber et al. 2001) . Noticeably, the engagement of activating FccR by unrelated immune complexes was found to inhibit the replication of HIV-1 in primary human macrophages (David et al. 2006) . Rather than being protective, antibodies can favor or aggravate viral infection. Anti-Spike antibodies, a viral protein which enables the severe acute respiratory syndrome (SRAS) coronavirus to infect epithelial cells, can prevent these cells from being infected. Anti-spike antibodies, however, can enable the infection of human immune cells through their interaction with FccR (Jaume et al. 2011 ). Likewise, antibodies may enhance HIV infection. Antibodies in complex with the gp120 protein of HIV indeed bind to FccR (Fust 1997) . Receptor aggregation that ensues enables the internalization of antibody-HIV complexes and, as a consequence, monocytes infection (Jouault et al. 1991) .

Interestingly, FcRs may promote viral infection by inducing an antibodyindependent immunosuppression. Nucleoplasmid proteins of the measle virus were indeed found to bind to murine and human FccRII, and this binding was found to inhibit antibody production by human B cells. This mechanism was proposed to account for the well-known immunosuppression associated with measles infection (Ravanel et al. 1997 ).

Specific antibodies are well known to neutralize bacterial toxins. Unexpectedly, the neutralization of B. anthacis toxin was recently found to depend on the engagement of FcRs (Abboud et al. 2010) .

FcRs are involved in antibody-dependent clearance of bacteria such as Legionella (Joller et al. 2010) , Salmonella (Tobar et al. 2004) or Toxoplasma (Joiner et al. 1990 ) through phagocytosis. FcRc-deficient mice fail to control Leishmania major (Padigel and Farrell 2005) or Mycobacterium tuberculosis (Maglione et al. 2008) infection, whereas FccRIIB-deficient mice display an enhanced resistance to these bacteria. FccRIIIA seem to play a predominant role in protection (Thomas and Buxbaum 2008) , but FccRI may contribute to protect from Bordello pertussis infection (Ioan-Facsinay et al. 2002) .

Like the measles virus, some bacteria can bind to FcRs expressed by immune cells, even when not in complex with antibodies. This interaction facilitates infection. Escherichia coli K1 express the outer membrane protein A (OmpA), which binds to FccRI on macrophages. This binding has two consequences. It facilitates the entry of bacteria into cells and it prevents the phosphorylation of FcRc (Mittal et al. 2010) . FccRI-deficient mice are resistant to E. coli infection.

IgE antibodies are well-known inducers of allergic reactions when engaging FceRI expressed by mast cells and basophils in experimental animals and in human patients (Dombrowicz et al. 1993 (Dombrowicz et al. , 1996 Wershil et al. 1987; Arimura et al. 1990; Fung-Leung et al. 1996) . One intriguing question is why mast cells, but not basophils, account for IgE-mediated, FceRI-dependent PSA, and where are the responsible mast cells located. The contributions to allergic symptoms of FceRI expressed by eosinophils (Tanaka et al. 1995) , monocytes (Maurer et al. 1994) , alveolar macrophages (Ochiai et al. 1996) , neutrophils (Gounni et al. 2001 ) and platelets (Joseph et al. 1997) in patients with high IgE levels can be expected to be different in allergies that affect different tissues. They remain to be delineated. Unlike the well-established role of FccRs in experimental anaphylaxis, the role of FccRs in human allergies is far from being clear. The ability of human FccRs to induce allergic reactions was demonstrated using transgenic mice Mancardi et al. 2013) . Both human FccRI and FccRIIA triggered IgGinduced PSA and ASA. FccRIIA expressed by mast cells were also responsible for IgG-induced PCA. Human skin mast cells express FccRIIA, but no FccRIIB (Zhao et al. 2006) . Interestingly, a mouse deficient for all endogenous FccR and transgenic for all human FccR underwent anaphylaxis following an injection of aggregated human IgG (Smith et al. 2012) .

Here again, the type of cells that express FccRs, and especially the FccRIIA/ FccRIIB ratio, has a decisive influence on the outcome. This ratio is high in human neutrophils and these cells respond robustly to IgG immune complexes. In accordance with this in vitro observation, the transfert of human neutrophils restored anaphylaxis in FcRc-deficient mice ). This ratio is very low in human basophils, and these cells do not respond to the same immune complexes. IgG receptors expressed by human basophils indeed function as inhibitors of cell activation, and IgG immune complexes that co-engaged FccR with FceRI on basophils inhibited IgE-dependent basophil activation in all normal donors tested (Cassard et al. 2012 ).

Autoimune diseases that depend on autoantibodies involve an unbalance between activating and inhibitory FcRs. Activating FcRs account for the clinical expression of autoimunity in several murine models. FcRc-deficient mice were protected from multiple sclerosis (Robbie-Ryan et al. 2003) , did not develop anti-platelet-induced thrombocytopenic purpura (Fossati-Jimack et al. 1999 ) and displayed less lesions in a model of Parkinson disease (He et al. 2002) . FccRI , FccRIIIA (Fossati-Jimack et al. 1999) and FccRIV were found to contribute to platelet depletion, to systemic lupus erythematosus (Seres et al. 1998) , to experimental hemolytic anemia (Meyer et al. 1998; Syed et al. 2009 ), to glomerulonephritis (Fujii et al. 2003) and to arthritis (Ioan-Facsinay et al. 2002; Bruhns et al. 2003; Mancardi et al. 2011) .

Autoantibodies induced thrombocytopenic purpura (Reilly et al. 1994) or arthritis (Pietersz et al. 2009 ) in transgenic mice expressing human FccRIIA, and the expression of human FccRI in FcRc-deficient mice restored joint inflammation in the K/BxN model of rheumatoid arthritis (Mancardi et al. 2013 ) Autoantibodies against myelin found in multiple sclerosis, and autaoantibodies against dopaminergic neurons found in Parkinson's disease (McRae-Degueurce et al. 1988 ) are thought to induce inflammation by activating FcR-expressing phagocytic cells. Many cells of the central nervous system express FcRs, and immune cells are recruited from the bloodstream into the brain in these disorders.

Conversely, FccRIIB prevent autoimmunity. FccRIIB-deficient C57BL/6 mice spontaneously develop autoimmune diseases when ageing, with anti-DNA and anti-chromatin antibodies, and they die of glomerulonephritis (Ravetch and Bolland 2001) . Importantly, the partial restoration of FccRIIB levels on B cells in lupus-prone mouse strains was sufficient to restore tolerance and to prevent disease, suggesting that minor alterations of FccRIIB expression may be sufficient to induce autoimmunity (McGaha et al. 2005; Mackay et al. 2006) . A polymorphism in the transmembrane domain of human FccRIIB was found to decrease the ability to translocate into lipd rafts and to inhibit BCR signaling (Kono et al. 2005 ).

Anti-tumor antibodies can lead to a significant reduction of tumor mass when injected in wt mice , but not in FcRc-deficient mice (Clynes et al. 1998) . FccRIIIA (Albanesi et al. 2012 ), but also FccRI (Bevaart et al. 2006) and FccRIV have been reported to participate to the reaction. The anti-tumor effects of anti-tumor antibodies were markedly enhanced in FccRIIB-deficient mice (Clynes et al. 2000) . Antibody-dependent cell-mediated cytotoxicity is thought to account for these in vivo effects (Koene et al. 1997 ) and, as discussed below, it has provided the grounds for passive immunotherapy of cancer. The nature of effector cells is unclear. Cell-depletion experiments suggested a role for monocytes/macrophages (Otten et al. 2008 ) and possibly other myeloid cells, besides NK cells. Anti-tumor antibodies can have an opposite effect and enhance tumor growth. An intravenous injection of antibodies against antigen expressed by tumor cells can indeed prevent the rejection of allogeneic tumor cells injected subcutaneously, leading to the death of mice which, otherwise, clear their tumors within 2 weeks (Voisin 1971) . In spite of extensive investigation, the mechanism of this long known enhancement phenomenon (Kaliss 1958) has remained largely unknown. We recently found that enhancement is abrogated in FccRIIB-deficient mice (Getahun et al. unpublished) .

Antibodies appear as potent effector molecules. They are, however, not ''magic bullets'' as they are sometimes viewed, in reference to Paul Ehrlich's chemical compounds with a selective affinity for pathogens (Strebhardt and Ullrich 2008) . As discussed in this review, their action is more subtle. They engage multiple receptors with adaptative structures and signaling on a variety of cells with adaptive functional responses, which enables immune responses to adapt to the infinite varitions of antigenic stimulations. Taking into account the complexity of interactions between antigens, antibodies, FcRs and cells occuring here and there in the body is not only an exciting challenge, it has become a requirement for understanding the pathogenesis of disease and for developing new therapeutic tools. One can indeed exploit this complexity to ameliorate immunotherapy and to conceive new antibody-dependent approaches of a variety of diseases.

In various immune diseases, symptoms are the local manifestations of a systemic process. Allergies and autoimmune disorders, in which antigen is either applied or present locally, are examples of such diseases. They develop at the intersection of a plurality of systemic effectors and of a plurality of tissue effectors. This may also apply to local or tissue-specific infections in which symptoms are primarily due to the anti-pathogen immune response. Thus, if one takes the example of allergies, the clinical manifestations of cutaneous allergies and of respiratory allergies depend on effector cells present in the skin and in the respiratory tract, respectively, and on target organs that do not respond identically to inflammatory mediators secreted by effector cells. Better understanding the polymorphism of allergies is a mean to better treat them.

Antibodies against molecules expressed by target cells have been increasingly used for passive immunotherapy, aiming at engaging FcRs to induce phagocytosis and/or ADCC by FcR-expressing effector cells and destroy target cells. Thus, the anti-CD20 antibody Rituximab has been used to kill CD20-expressing transformed B cells (Manches et al. 2003) , or B cells responsible for the production of pathogenic autoantibodies in rheumatoid arthritis (Shaw et al. 2003; Edwards et al. 2004) . When binding to HER2, Trastuzumab not only inhibits the proliferation of breast, ovary or lung cancer cells by preventing receptor dimerization (Yakes et al. 2002) , it also induces tumor destruction by engaging activating FcRs on cytotoxic cells (Clynes et al. 2000) . Antibodies against molecules expressed by dendritic cells can also enhance antigen presentation and, as a consequence, T-cell dependent cytotoxicity against tumor cells. Unexpectedly, this effect was found to involve FccRIIB (Li and Ravetch 2011) . Indeed, when binding in trans to FccRIIB-expressing cells by their Fc portion, anti-TNF receptors antibodies mimic the effect of multimeric ligands and they aggregate TNF receptors much more efficiently than when they do not (Li and Ravetch 2013) .

Likewise, the therapeutic effect of Omalizumab, a monoclonal antibody directed against the FceRI-binding site of IgE developed to prevent mast cell and basophil sensitization by IgE in allergic patients, happened to be mediated by an unanticipated mechanism. Omalizumab indeed forms IgE-anti-IgE complexes that are rapidly degraded, probably through internalization. As a result, serum IgE become undetectable (Djukanovic et al. 2004) . As the half-life of FceRI is decreased when they are not occupied by IgE, basophils and mast cells have a markedly reduced FceRI expression.

The efficacy of therapeutic antibodies having been established, one can now aim at enhancing their wanted effects while decreasing their unwanted effects. The situation is simpler than in active immune responses because therapeutic antibodies are directed against a single epitope, because they are mono-isotypic and because most are humanized antibodies made by grafting antigen-specific variable sequences onto the same human backbone (the constant domains of a well-know human IgG1 in many cases). Thus, one can engineer therapeutic antibodies so that they have specific properties. One can mutate the main glycosylation site (e.g., introduce a N297Q point mutation in the Fc portion) to generate antibodies that can bind to target antigens without engaging FcRs except FcRn, which preserves their half life (Veri et al. 2007) . One can increase the half life of antibodies by generating mutations that enhance the affinity of the Fc portion for FcRn (Ward and Ober 2009) . As a consequence, the plasma concentration of therapeutic antibodies is increased (Dall'Acqua et al. 2006) . One can either change the glycosylation or generate mutations that enhance the affinity of antibodies for activating FcRs. Thus, mutations that remove fucose residues from the Fc portion of antibodies, enhance their affinity for human FccRIIIA (Natsume et al. 2005; Niwa et al. 2005) . Conversely, one can generate antibodies with mutations in the Fc portion that enhance the affinity of antibodies for inhibitory FcRs. Thus, antihuman CD19 antibodies that bind to FccRIIB with a several hundred-fold higher affinity than nonmutated antibodies, suppressed BCR-dependent activation of B cells from healthy donors or from SLE patients, reduced serum IgM, IgG, and IgE levels in SCID mice engrafted with SLE PBMC, and increased survival of mice engrafted with PBMC from a SLE patient (Horton et al. 2011) . Likewise, anti-IgE antibodies with an Fc portion having an increased affinity for FccRIIB further reduced free and total IgE levels by preventing the generation of IgE-secreting plasma cells (Chu et al. 2012) .

A step forward may be to know which cell types and which FcRs will be engaged by a given antibody, depending on the location of target cells or molecules, and to use therapeutic antibodies that will preferentially engage the desired FcRs on the appropriate effector cells. Phenotyping FcRs on effector cells in individual patients and assessing their ability to activate these cells would indeed be a progress toward personalized medicine.

Generating new vaccines remains a major challenge for immunologists. Antibodies are responsible for the protective effects of the overwhelming majority of vaccines. Neutralizing antibodies keep being thought to account for protection and, in most cases, FcR-dependent mechanisms are ignored. Different strategies may be necessary for vaccines against systemic infections and for local infections. Also, as exemplified by anti-SARS coronavirus antibodies, one wants to prevent antibodies from enabling the virus to infect FcR-expressing cells that are not infected in the absence of antibodies (Jaume et al. 2011) . No protective anti-cancer vaccine is available yet, and efforts are being made to induce and/or amplify cell-mediated cytotoxicity against tumor cells. The efficacy of passively administered therapeutic anti-tumor antibodies, however, suggests that vaccines that would generate such antibodies may be useful. Knowing how to induce antibodies with a therapeutic benefit, but not antibodies with tumor enhancing properties will require that mechanisms of antibody-dependent enhancement are understood.

Finally, if, as discussed here, antibodies can exert a whole array of biological effects, one may stop thinking of vaccines only as a mean to kill, destroy or remove unwanted molecules, cells or pathogens. We recently found that, when coengaged with a growth factor receptor, FccRIIB could inhibit the proliferation of transformed tumor cells (Malbec and Daëron 2012) . On the basis of this observation, vaccines could aim at co-engaging a variety of target antigens with inhibitory receptors and interfere with pathogenic processes due to cell activation or proliferation. This would extend the field of application of vaccines to diseases other than infectious diseases and cancer, such as inflammatory diseases. Specific immunotherapy of allergy is an example. It was proposed one century ago, and it has being used since then. Its efficacy and indications, however, remain limited. They might be markedly enhanced if the mechanisms behind this empirical maneuver were better known and exploited.

A requirement for FcgammaR in antibody-mediated bacterial toxin neutralization

Cutting edge: FcgammaRIII (CD16) and FcgammaRI (CD64) are responsible for anti-glycoprotein 75 monoclonal antibody TA99 therapy for experimental metastatic B16 melanoma

Cytoplasmic domain heterogeneity and functions of IgG Fc receptors in B lymphocytes

Active and passive cutaneous anaphylaxis in WBB6F1 mouse, a mast cell-deficient strain

The impact of glycosylation on the biological function and structure of human immunoglobulins

Characterization of a critical binding site for human polymeric Ig on secretory component

Ueber das Zustandekommen der Diphtherie-Immunit€at und der Tetanus-Immunit€at bei Thieren

The highaffinity IgG receptor, FcgammaRI, plays a central role in antibody therapy of experimental melanoma

Compartmentalization of ITAM and integrin signaling by adapter molecules

Specificity and affinity of human Fcgamma receptors and their polymorphic variants for human IgG subclasses

Colony-stimulating factor-1-dependent macrophages are responsible for IVIG protection in antibody-induced autoimmune disease

Molecular basis of the recruitment of the SH2 domain-containing inositol 5-phosphatases SHIP1 and SHIP2 by fcgamma RIIB

Crystal structure of the complex of rat neonatal Fc receptor with Fc

New nomenclature for the Reth motif (or ARH1/TAM/ARAM/YXXL)

Modulation of tumor growth by inhibitory Fc(gamma) receptor expressed by human melanoma cells

Fcgamma receptors inhibit mouse and human basophil activation

Different patterns of calcium signaling triggered through two components of the B lymphocyte antigen receptor

Reduction of total IgE by targeted coengagement of IgE B-cell receptor and FcgammaRIIb with Fc-engineered antibody

Fc receptors are required in passive and active immunity to melanoma

Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets

Fc epsilon RII/CD23: the low affinity receptor for IgE

Allogenic mast cell degranulation induced by histocompatibility antibodies: an in vitro model of transplantation anaphylaxis

Immunoreceptor tyrosine-based inhibition motifs: a quest in the past and future

The same tyrosine-based inhibition motif, in the intracytoplasmic domain of FcgRIIB, regulates negatively BCR-, TCR-, and FcR-dependent cell activation

Regulation of high-affinity IgE receptor-mediated mast cell activation by murine low-affinity IgG receptors

H-2 antigens, on mast cell membrane, as target antigens for anaphylactic degranulation

Properties of human IgG1s engineered for enhanced binding to the neonatal Fc receptor (FcRn)

The engagement of activating FcgammaRs inhibits primate lentivirus replication in human macrophages

Phenotypic and functional characterization of human TCR gamma delta + intestinal intraepithelial lymphocytes

The low affinity Fc receptor for IgG functions as an effective cytolytic receptor for self-specific CD8 T cells

Crystal structure of the ectodomain of human FcalphaRI

Effects of treatment with antiimmunoglobulin E antibody omalizumab on airway inflammation in allergic asthma

Anaphylaxis mediated through a humanized high affinity IgE receptor

Abolition of anaphylaxis by targeted disruption of the high affinity immunoglobulin E receptor alpha chain gene

Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis

Follicular dendritic cell (FDC)-FcgammaRIIB engagement via immune complexes induces the activated FDC phenotype associated with secondary follicle development

T-independent antibody responses to Tdependent antigens: a novel follicular dendritic cell-dependent activity

Cre-mediated cell ablation contests mast cell contribution in models of antibody-and T cell-mediated autoimmunity

High pathogenic potential of low-affinity autoantibodies in experimental autoimmune hemolytic anemia

Predominant role of FcgammaRIII in the induction of accelerated nephrotoxic glomerulonephritis

Transgenic mice expressing the human high-affinity immunoglobulin (Ig) E receptor alpha chain respond to human IgE in mast cell degranulation and in allergic reactions

Enhancing antibodies in HIV infection

Crystal structure of the human high-affinity IgE receptor

IgE enhances antibody and T cell responses in vivo via CD23 + B cells

Multiple roles for the major histocompatibility complex class Irelated receptor FcRn

SHIP down-regulates FcepsilonR1-induced degranulation at supraoptimal IgE or antigen levels

The high-affinity IgE receptor on eosinophils: from allergy to parasites or from parasites to allergy?

Human neutrophils express the high-affinity receptor for immunoglobulin E (Fc epsilon RI): role in asthma

Role of Fcgamma receptors in nigral cell injury induced by Parkinson disease immunoglobulin injection into mouse substantia nigra

Competition of 19S and 7S antigen receptors in the regulation of the primary immune response

De la transfusion péritonéale

The immune complex: possible ways of regulating the antibody response

No evidence for a role of FcgammaRIIB in suppression of in vivo antibody responses to erythrocytes by passively administered IgG

Antibody-mediated regulation of the immune response

Antibody-mediated coengagement of FcgammaRIIb and B cell receptor complex suppresses humoral immunity in systemic lupus erythematosus

The src homology 2-containing inositol phosphatase (SHIP) is the gatekeeper of mast cell degranulation

Fc receptor-mediated phagocytosis makes a significant contribution to clearance of influenza virus infections

Molecular basis of Fc receptor function

FcgammaRI (CD64) contributes substantially to severity of arthritis, hypersensitivity responses, and protection from bacterial infection

Physico-chemical properties of human reaginic antibody. IV. Presence of a unique immunoglobulin as a carrier of reaginic activity

Requirement for a beta 2-microglobulin-associated Fc receptor for acquisition of maternal IgG by fetal and neonatal mice

Anti-severe acute respiratory syndrome coronavirus spike antibodies trigger infection of human immune cells via a pH-and cysteine protease-independent FcgammaR pathway

Toxoplasma gondii: fusion competence of parasitophorous vacuoles in Fc receptor-transfected fibroblasts

Antibodies protect against intracellular bacteria by Fc receptor-mediated lysosomal targeting

Mouse and human neutrophils induce anaphylaxis

Human FcgammaRIIA induces anaphylactic and allergic reactions

Expression and functions of the high-affinity IgE receptor on human platelets and megakaryocyte precursors

Infection of monocytic cells by HIV1: combined role of FcR and CD4

Inducing tumor immunity through the selective engagement of activating Fcgamma receptors on dendritic cells

Anaphylaxis: mechanisms of mast cell activation

Immunological enhancement of tumor homografts in mice: a review

Efficient IgGmediated suppression of primary antibody responses in Fcgamma receptor-deficient mice

CD23 trimers are preassociated on the cell surface even in the absence of its ligand. IgE

The high-affinity IgE receptor (Fc epsilon RI): from physiology to pathology

Isolation and characterization of cDNAs coding for the beta subunit of the high-affinity receptor for immunoglobulin E

Fc gammaRIIIa-158 V/F polymorphism influences the binding of IgG by natural killer cell Fc gammaRIIIa, independently of the Fc gammaRIIIa-48L/R/H phenotype

FcgammaRIIB Ile232Thr transmembrane polymorphism associated with human systemic lupus erythematosus decreases affinity to lipid rafts and attenuates inhibitory effects on B cell receptor signaling

The interaction of IgE with rat basophilic leukemia cells. II. Quantitative aspects of the binding reaction

Insufficient phosphorylation prevents fc gamma RIIB from recruiting the SH2 domain-containing protein-tyrosine phosphatase SHP-1

Dynamic interactions of Fc gamma receptor IIB with filamin-bound SHIP1 amplify filamentous actin-dependent negative regulation of Fc epsilon receptor I signaling

Steric masking of a dilysine endoplasmic reticulum retention motif during assembly of the human high affinity receptor for immunoglobulin E

Inhibitory Fcgamma receptor engagement drives adjuvant and antitumor activities of agonistic CD40 antibodies

Antitumor activities of agonistic anti-TNFR antibodies require differential FcgammaRIIB coengagement in vivo

Intracellular degradation of Fc gamma RIII in mouse bone marrow culture-derived progenitor mast cells prevents its surface expression and associated function

Regulation of immune responses through inhibitory receptors

Class I-restricted presentation of exogenous antigen acquired by Fcgamma receptor-mediated endocytosis is regulated in dendritic cells

Selective dysregulation of the FcgammaIIB receptor on memory B cells in SLE

Fc gamma receptors regulate immune activation and susceptibility during Mycobacterium tuberculosis infection

The control effect of histamine on body temperature and respiratory function in IgE-dependent systemic anaphylaxis

Antibodies against growth factor receptors can inhibit the proliferation of transformed cells via a cis-interaction with inhibitory FcR

Fc epsilon receptor I-associated lyn-dependent phosphorylation of Fc gamma receptor IIB during negative regulation of mast cell activation

Linker for activation of T cells integrates positive and negative signaling in mast cells

Peritoneal cell-derived mast cells: an in vitro model of mature serosal-type mouse mast cells

Antibodies mediate intracellular immunity through tripartite motif-containing 21 (TRIM21)

The high-affinity human IgG receptor FcgammaRI (CD64) promotes IgGmediated inflammation, anaphylaxis, and antitumor immunotherapy

FcgammaRIV is a mouse IgE receptor that resembles macrophage FcepsilonRI in humans and promotes IgEinduced lung inflammation

Cutting Edge: The murine high-affinity IgG receptor FcgammaRIV is sufficient for autoantibody-induced arthritis

In vitro mechanisms of action of rituximab on primary non-Hodgkin lymphomas

Expression of functional high affinity immunoglobulin E receptors (Fc epsilon RI) on monocytes of atopic individuals

Crystal structure of the human leukocyte Fc receptor Fc gammaRIIa

Restoration of tolerance in lupus by targeted inhibitory receptor expression

Immunocytochemical investigations on the presence of neuron-specific antibodies in the CSF of Parkinson's disease cases

Transmembrane signaling: the joy of aggregation

FcgammaRIII (CD16)-deficient mice show IgG isotype-dependent protection to experimental autoimmune hemolytic anemia

Fcgamma receptor I alpha chain (CD64) expression in macrophages is critical for the onset of meningitis by Escherichia coli K1

Assessment of the cardiopulmonary changes, mast cell degranulation, and death associated with active or IgE-or IgG1-dependent passive anaphylaxis

T cell-independent antigens type 2

Major histocompatibility complex class I-specific receptors on human natural killer and T lymphocytes

The Src homology 2 domain-containing inositol 5-phosphatase negatively regulates Fcgamma receptor-mediated phagocytosis through immunoreceptor tyrosine-based activation motif-bearing phagocytic receptors

Fucose removal from complex-type oligosaccharide enhances the antibodydependent cellular cytotoxicity of single-gene-encoded antibody comprising a single-chain antibody linked the antibody constant region

FcgammaRIV: a novel FcR with distinct IgG subclass specificity

Divergent immunoglobulin g subclass activity through selective Fc receptor binding

Enhanced natural killer cell binding and activation by low-fucose IgG1 antibody results in potent antibody-dependent cellular cytotoxicity induction at lower antigen density

Expression of high-affinity IgE receptor (Fc epsilon RI) on human alveolar macrophages from atopic and non-atopic patients

Basophils orchestrate chronic allergic dermatitis and protective immunity against helminths

Family of disulphide-linked dimers containing the zeta and eta chains of the T-cell receptor and the gamma chain of Fc receptors

Experimental antibody therapy of liver metastases reveals functional redundancy between Fc gammaRI and Fc gammaRIV

Cutaneous anaphylaxis in the albino rat

Quantitative studies in passive cutaneous anaphylaxis of the guinea pig

Control of infection with Leishmania major in susceptible BALB/c mice lacking the common gamma-chain for FcR is associated with reduced production of IL-10 and TGF-beta by parasitized cells

Sur les maladies virulentes, et en particulier sur la maladie appelée vulgairement choléra des poules

Murine natural killer cells express functional Fcg receptor II encoded by the FcgRa gene

Fc-dependent inhibition of mouse B cell activation by whole antimu antibodies

Inhibition of destructive autoimmune arthritis in FcgammaRIIa transgenic mice by small chemical entities

Alteration of the Fc gamma RIIa dimer interface affects receptor signaling but not ligand binding

Measles virus nucleocapsid protein binds to FcgammaRII and inhibits human B cell antibody production

IgG Fc receptors

Fc receptors

Genetic diversity in human Fc receptor II for immunoglobulin G: Fc gamma receptor IIA ligand-binding polymorphism

Antigen receptor tail clue

De l'anaphylaxie en général et de l'anaphylaxie par la mytilocongestive en particulier

De l'action anaphylactique de certains venins

Cutting edge: both activating and inhibitory Fc receptors expressed on mast cells regulate experimental allergic encephalomyelitis disease severity

Receptor-mediated transport of IgG

In vitro and in vivo activation of murine gamma/delta T cells induces the expression of IgA, IgM, and IgG Fc receptors

Correlation of Fc gamma receptor expression of monocytes with clearance function by macrophages in systemic lupus erythematosus

B cell therapy for rheumatoid arthritis: the rituximab (anti-CD20) experience

Mouse model recapitulating human Fcgamma receptor structural and functional diversity

Crystal structure of the soluble form of the human fcgamma-receptor IIb: a new member of the immunoglobulin superfamily at 1.7 A resolution

Paul Ehrlich's magic bullet concept: 100 years of progress

Both FcgammaRIV and FcgammaRIII are essential receptors mediating type II and type III autoimmune responses via FcRgamma-LAT-dependent generation of C5a

FcR gamma chain deletion results in pleiotrophic effector cell defects

Identification of the low affinity receptor for immunoglobulin E on mouse mast cells and macrophages as Fc gamma RII and Fc gamma RIII

High affinity IgE receptor (Fc epsilon RI) expression on eosinophils infiltrating the lesions and mite patch tested sites in atopic dermatitis

Follicular dendritic cells: beyond the necessity of T-cell help

FcgammaRIII mediates immunoglobulin G-induced interleukin-10 and is required for chronic Leishmania mexicana lesions

Salmonella escape from antigen presentation can be overcome by targeting bacteria to Fc gamma receptors on dendritic cells

Phenotypic variation in IgG receptors by nonclassical FCGR2C alleles

Monoclonal antibodies capable of discriminating the human inhibitory Fcgammareceptor IIB (CD32B) from the activating Fcgamma-receptor IIA (CD32A): biochemical, biological and functional characterization

Immunological facilitation, a broadening of the concept of the enhancement phenomenon

Chapter 4: multitasking by exploitation of intracellular transport functions the many faces of FcRn

125I-fibrin deposition in IgE-dependent immediate hypersensitivity reactions in mouse skin. Demonstration of the role of mast cells using genetically mast cell-deficient mice locally reconstituted with cultured mast cells

Theory of equilibrium binding of asymmetric bivalent haptens to cell surface antibody: application to histamine release from basophils

Identification and characterization of lymphoid precursors in the murine intestinal epithelium

Immune complex-bearing follicular dendritic cells deliver a late antigenic signal that promotes somatic hypermutation

Herceptin-induced inhibition of phosphatidylinositol-3 kinase and Akt Is required for antibody-mediated effects on p27, cyclin D1, and antitumor action

Fc gamma RIIa, not Fc gamma RIIb, is constitutively and functionally expressed on skin-derived human mast cells

Acknowledgments I am indebted to my mentors, colleagues, collaborators, and students who triggered, encouraged, consolidated and fed my long-lasting interest for Fc receptors. I am grateful to Dr. Fritz Melchers who expressed his interest throughout the years, and who critically discussed a preliminary version of this work.